Back
69
Day Range
$65.67
$67.46
52-Week Range
$60.70
$88.20
Volume
1,022,847
50D / 200D Avg
$75.06
/
$75.07
Prev Close
$65.78
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 7.3 | 0.4 |
| P/B | 2.3 | 2.9 |
| ROE % | 38.9 | 3.7 |
| Net Margin % | 18.7 | 3.8 |
| Rev Growth 5Y % | 0.5 | 10.0 |
| D/E | 1.0 | 0.2 |
Key Takeaways
Revenue grew 0.47% annually over 5 years — modest growth
Earnings grew 224.84% over the past year
ROE of 38.86% indicates high profitability
Net margin of 18.69% shows strong profitability
Negative free cash flow of -10.00M
P/E of 7.32 — trading at a low valuation
Growth
Revenue Growth (5Y)
0.47%
Revenue (1Y)0.86%
Earnings (1Y)224.84%
FCF Growth (3Y)N/A
Quality
Return on Equity
38.86%
ROIC16.22%
Net Margin18.69%
Op. Margin26.20%
Safety
Debt / Equity
1.00
Current Ratio1.23
Interest Coverage6.29
Valuation
P/E Ratio
7.32
P/B Ratio2.26
EV/EBITDA7.13
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 0.86% | Revenue Growth (3Y) | 0.78% |
| Earnings Growth (1Y) | 224.84% | Earnings Growth (3Y) | 7.52% |
| Revenue Growth (5Y) | 0.47% | Earnings Growth (5Y) | 1.60% |
| Profitability | |||
| Revenue (TTM) | 8.33B | Net Income (TTM) | 1.56B |
| ROE | 38.86% | ROA | 10.89% |
| Gross Margin | 53.47% | Operating Margin | 26.20% |
| Net Margin | 18.69% | Free Cash Flow (TTM) | -10.00M |
| ROIC | 16.22% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 1.00 | Current Ratio | 1.23 |
| Interest Coverage | 6.29 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | 7.32 | P/B Ratio | 2.26 |
| P/S Ratio | 1.37 | PEG Ratio | 0.04 |
| EV/EBITDA | 7.13 | Dividend Yield | 0.00% |
| Market Cap | 11.40B | Enterprise Value | 15.55B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 8.33B | 8.25B | 8.20B | 8.13B | 8.17B |
| Net Income | 1.56B | 479.00M | 1.35B | 1.34B | 1.46B |
| EPS (Diluted) | 8.88 | 2.76 | 7.79 | 7.79 | 8.47 |
| Gross Profit | 4.45B | 4.59B | 4.69B | 4.70B | 4.92B |
| Operating Income | 2.18B | 1.04B | 1.69B | 1.69B | 1.88B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 14.29B | 14.46B | 13.94B | 13.59B | 14.08B |
| Total Liabilities | 9.25B | 11.50B | 2.28B | 1.85B | 2.02B |
| Shareholders' Equity | 5.05B | 2.96B | 11.67B | 11.74B | 12.06B |
| Total Debt | 5.04B | 8.01B | 8.30B | 0.0 | 0.0 |
| Cash & Equivalents | 878.00M | 762.00M | 194.00M | 61.00M | 91.00M |
| Current Assets | 3.86B | 3.25B | 2.52B | 2.23B | 2.19B |
| Current Liabilities | 3.14B | 2.70B | 1.73B | 1.31B | 1.41B |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#55 of 658
Recent Activity
Entered
Contrarian Investing (David Dreman)
Mar 24, 2026